Forty years after Congress passed the Drug Price Competition and Patent Term Restoration Act of 1984, the law’s core tension […]

The Orange Book and Purple Book are not regulatory housekeeping. They are the official ledgers where billions of dollars of

More than $200 billion in pharmaceutical revenue faces patent expiry through 2030, with some analyst projections reaching $300 billion. For

Generic drugs account for 90% of U.S. prescriptions yet only 17.5% of total drug spending. That math is possible because

The gap between developing a generic drug and a biosimilar is not regulatory paperwork. It is the difference between a

Why the Patent Cliff Is the Pharmaceutical Industry’s Most Predictable Crisis — and the Generic Industry’s Biggest Opportunity Every dollar

When Paragraph IV filings hit the docket, they set off a chain of financial events most analysts only half-understand. Here

Every pharmaceutical analyst knows when the compound patent expires. It is on the Bloomberg terminal, in the 10-K, in every

The average branded drug reaches pharmacy shelves with roughly 10 to 12 years of effective patent life remaining. The average